Physician profile
John J Carter
NPI 1821583329
$90,385.91
in general payments reported to CMS, 2019-2025
32 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,867 · 2022: $2,115 · 2023: $18K · 2024: $31K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $17K · Food and Beverage: $12K · Travel and Lodging: $6,336 · Education: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,694.00 |
| Consulting Fee | $17,062.50 |
| Food and Beverage | $11,864.76 |
| Travel and Lodging | $6,336.24 |
| Education | $445.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $75,936.77 | 2021-2025 | Ingrezza |
| Abbvie INC. | $2,641.36 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,196.08 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,355.15 | 2021-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $1,340.70 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,326.89 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $996.67 | 2021-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $920.57 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $736.55 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $477.76 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $383.69 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $323.63 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $314.89 | 2022-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $296.11 | 2021-2024 | Qelbree |
| Noven Therapeutics, LLC | $146.15 | 2021-2024 | Xelstrym, Secuado |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $145.62 | 2021-2024 | |
| Avanir Pharmaceuticals, INC. | $124.09 | 2022 | |
| Sunovion Pharmaceuticals INC. | $124.07 | 2021 | |
| Ironshore Pharmaceuticals INC. | $90.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $62.65 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $61.58 | 2025 | Jornay Pm |
| Novo Nordisk INC | $59.36 | 2021-2023 | Wegovy |
| Almatica Pharma LLC | $56.97 | 2021 | |
| Neuronetics, INC. | $52.61 | 2023-2024 | Neurostar Tms Therapy System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.22 | 2023-2025 | |
| Bausch Health US, LLC | $41.79 | 2021 | |
| Livanova USA, INC. | $36.60 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Indivior INC. | $29.60 | 2024 | Perseris |
| Bioxcel Therapeutics, INC. | $19.35 | 2023 | Igalmi |
| Allergan, INC. | $15.71 | 2021 | |
| Noven Pharmaceuticals, INC. | $12.41 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.